🇺🇸 FDA

Company profile · Sponsor

AXIM

AXIM BIOTECHNOLOGIES, INC.

AXIM · NYSE biotech SAN DIEGO, CA, USA
Pipeline
20
Drugs
5
Patents
8

Quick answer

AXIM (AXIM) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 20 pipeline programs, 5 drugs, and 8 patents to this profile..

Company facts

Ticker AXIM
Exchange NYSE
Company type biotech
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001514946

Pipeline (20)

Search pipeline →

  1. Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion

    AXIM

    B-cell Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial

  2. IVEMEND 150 mg powder for solution for infusion, Aprepitant Placebo Tablet, Aprepitant Teva 80 mg, harde capsules, NaCl I.V.

    AXIM

    Delayed chemotherapy induced nausea and vomiting (CINV)

    phase 3 small molecule active

    1 trial

  3. Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution

    AXIM

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  4. ANAKINRA

    AXIM

    Hyperinflammation, Sepsis

    phase 2 small molecule active

    1 trial

  5. Anti-GD2-800CW

    AXIM

    Neuroblastoma

    phase 2 small molecule active

    1 trial

  6. BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets

    AXIM

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

  7. Etoposide 20 mg/ml Concentrate for Solution for Infusion, Sodium Chloride 0.9% Intravenous Infusion BP, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Human Albumin Baxalta 50 g/l Solution for Infusion, Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion, Qarziba 4.5 mg/mL concentrate for solution for infusion, Dacarbazine Lipomed 200 mg powder for solu

    AXIM

    Neuroblastoma

    phase 2 small molecule active

    1 trial

  8. IOBENGUANE (123I) , 68Ga-SSO120

    AXIM

    neuroblastoma

    phase 2 small molecule active

    1 trial

  9. IOBENGUANE (123I) , [18F]meta-fluorobenzylguanidine

    AXIM

    (suspision on) Neuroblastoma

    phase 2 small molecule active

    1 trial

  10. Jakavi 5 mg tablets, Venetoclax, Jakavi 20 mg tablets, Venetoclax, Jakavi 10 mg tablets, Venetoclax, Venetoclax, Venetoclax, Venetoclax, Jakavi 15 mg tablets

    AXIM

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  11. MB-huCART19.1

    AXIM

    B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  12. ONC201, Paxalisib

    AXIM

    Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)

    phase 2 small molecule active

    1 trial

  13. Quizartinib

    AXIM

    newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML

    phase 2 small molecule active

    1 trial

  14. SPRYCEL 70 mg film-coated tablets, Venetoclax, SPRYCEL 100 mg film-coated tablets, Venetoclax, SPRYCEL 20 mg film-coated tablets, Venetoclax, SPRYCEL 50 mg film-coated tablets, Venetoclax, Venetoclax, Venetoclax, SPRYCEL 10 mg/mL powder for oral suspension

    AXIM

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  15. Tovorafenib, Tovorafenib

    AXIM

    craniopharyngioma

    phase 2 small molecule active

    1 trial

  16. Chewing Gum

    AXIM

    THC

    phase 1 small molecule active

    1 trial

  17. ONC206 Powder

    AXIM

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  18. Vyxeos Liposomal 44 mg/100 mg powder for concentrate for solution for infusion., Evoltra 1 mg/ml concentrate for solution for infusion

    AXIM

    AML

    phase 1 small molecule active

    1 trial

  19. WT1-loaded CBDC Vaccine

    AXIM

    AML: Acute Myeloid Leukemia/ cancer of blood and bone marrow

    phase 1 small molecule active

    1 trial

  20. Ziftomenib, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Solu-Cortef Powder for Solution for Injection or Infusion 100 mg

    AXIM

    Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

Drugs (5)

Search drugs →

  1. technetium tc-99m albumin aggregated kit

    MACROTEC

    INJECTION approved

  2. technetium tc-99m gluceptate kit

    GLUCOSCAN

    INJECTION approved

  3. technetium tc-99m lidofenin kit

    TECHNESCAN HIDA

    INJECTION approved

  4. technetium tc-99m mertiatide kit

    TECHNETIUM TC99M MERTIATIDE KIT

    INJECTION approved

  5. technetium tc-99m pentetate kit

    AN-DTPA

    INJECTION approved

Patents (8)

Search patents →

  1. US 12391732

    Articles comprising a silk polypeptide for antigen delivery

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12379385

    Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12318397

    Methods and compositions for testosterone production

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12290524

    Methods and compositions for testosterone production

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12171837

    Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12168718

    Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12144876

    Security mechanisms for radiopharmaceutical elution system and elution process

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12133890

    Antigen-binding polypeptide targeting B7H3 and application thereof

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is AXIM?

AXIM (AXIM) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 20 pipeline programs, 5 drugs, and 8 patents to this profile..

What pipeline programs does AXIM sponsor?

We track 20 ClinicalTrials.gov-linked programs for AXIM, including Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion and 19 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does AXIM company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.